BCAS2

Across TCGA pan-cancer cohorts, BCAS2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated BCAS2 data layer compared with 25 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher BCAS2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated BCAS2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and COAD show a favorable association.

LSCC, COAD, and GBM are the cancer types where BCAS2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	All	0.829	0.616	.014	23	view →
COAD	DFS	Median	All	1.000	0.889	.024	18	view →
GBM	DFS	Median	All	0.498	0.270	.013	5	view →
CCRCC	DFS	Tertile	All	0.681	1.000	.016	3	view →
PDAC	DFS	Median	All	0.862	0.728	.028	2	view →
LUAD	OS	Median	All	0.999	0.895	.047	1	view →
HNSC	DFS	Median	III,IV	1.000	0.937	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

BCAS2–LSCC (DFS)

Open the LSCC breakdown →